[Abstract] The construction of deletion-knockout poxviruses is a useful approach to determining the function of specific virus genes. This protocol is an adaptation of the transient dominant 
3. Purify the PCR products from step A2 using Qiaquick PCR purification (according to the manufacturers' recommendations).
4. Combine equimolar amounts of the PCR products from step A3 and carry out a further PCR using primers 1 & 4. This will result in a single PCR product of approximately 1.1 kb consisting of a region of the FWPV genome deleted for the GoI.
5. Purify the PCR product from step A4 using Qiaquick PCR purification.
6. Ligate the PCR product into the recombination vector (pGNR) using the selected/designed restriction enzymes (for guidance see Reference 4).
B. Making the recombinant fowlpox virus
Due to matching sequences between the recombination vector and fowlpox virus genome homologous recombination occurs resulting in recombinant viruses (A scheme of the recombination events can be found in Figure 4 , Reference 2.).
1. Seed a T25 tissue culture flask with 3.9 x 10 6 CEFs (to achieve 70% confluency the following day) in 5 ml 10% serum 199 media.
2. Remove media and infect CEFs with FWPV (to give a multiplicity of infection of 3 to 5) in 0.5 ml of serum-free DMEM.
3. Incubate for 2 h at 37 °C, 5% CO 2 with occasional rocking.
4. Add 3 ml 2% serum 199 media and leave for a further 2 h.
5. Prepare transfection mix [DNA (from step A6): 2 µg; serum-free DMEM: 200 µl; Polyfect:
10 µl ], pipette up and down a few times and leave at room temperature for 15-20 min (http://www.qiagen.com/knowledge-and-support/resource-center/resource-download.aspx ?id=bf924409-51f9-4bd0-b63f-a8369c70a331&lang=en).
6. Remove media from cells and wash with serum free DMEM media.
7. Add 3 ml 2% serum 199 media to cells.
8. Add transfection mix directly to flask and rock a few times to mix.
9. Incubate 37 °C, 5% CO 2 overnight.
10. The following day, replace the media in the T25 with 5 ml 2% serum 199 MXH media and incubate 37 °C, 5% CO 2 for a further 3 days.
11. Release progeny virus from cells by freeze thawing three times using a -80 °C freezer.
The protocol can be stopped at this stage and resumed when purification of the virus is required. It is not necessary to centrifuge the freeze-thawed mixture to remove cell debris. 
Note: Importantly and unusually, FWPV plaques are visible as opaque, not clear, areas! Their presence can be confirmed by broad field microscopy, preferably under phase contrast. Note also that MXH causes FWPV to replicate more slowly, resulting in smaller plaques so do not just select large plaques.
5. By eye mark the location of isolated plaques on the bottom of the plates with a fine marker pen, then pick individual plaques using cut-off filter tips (e.g. ART 200 G max, volume 200 µl ) into 500 µl serum free DMEM.
6. Freeze thaw the isolated plaque suspension three times (as previously).
7. Repeat steps C2-6 three times in order to ensure the virus is sufficiently homogenous.
Note: The above steps isolate single-crossover intermediate recombinant FWPV, each carrying two copies of the GoI, one of which is mutant, the other parental (A scheme of the recombination events can be found in Figure 4 in Reference 2.). In order to resolve the intermediate virus to derivatives lacking gpt and containing either parental or mutant GoI, further plaque purification in the absence of MXH selection is needed. Assuming the GoI is not essential or required for FWPV replication and plaque production in CEF, resolved derivatives containing parental or mutant GoI will be isolated at equal frequencies, as long as primers 1 and 4 are placed equidistant from the GoI. Equivalence of isolation frequency is therefore conversely a test of whether a GoI plays a significant role in FWPV replication
and plaque production in CEF.
8. Repeat plaque purification three further times in the absence of MXH.
Test plaques to determine if intermediate recombinant FWPV have resolved by infecting
CEFs in 6 well plates with 100 µl freeze thawed plaque purified virus (diluted in 2 ml 2%
http://www.bio-protocol.org/e1126 
